Areva to build Pb-212 production facility

12 March 2010

An Areva subsidiary is to build a new facility to produce medical-grade lead-212 for anticancer treatments. The facility, to be located at Areva Med’s Bessines site in western France, is scheduled to open in 2013.

Areva CEO Anne Lauvergeon said: “This project illustrates Areva’s capacity for innovation. We are delighted to contribute to the development of innovative medical solutions thanks to our core business activities.”

Lead-212 is used in innovative alpha radio-immunotherapy to combat cancer.


Related Articles
VT Nuclear Services secures UK contracts
Dissolution solution



Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.